The Heartbreak of Alzheimer’s That Millions Live Through
Imagine slowly losing pieces of yourself little by little. You forget your grandkid’s name, struggle to follow a simple recipe, get lost on streets you’ve walked for decades, or can no longer hold a full conversation without repeating the same question ten times. For your family, watching this fade away is just as agonizing—they become full-time caregivers, sacrificing their own rest, finances, and peace to care for someone they love who feels like a stranger day by day.
This is the reality of Alzheimer’s disease, and its early warning stage called Mild Cognitive Impairment (MCI). Right now, every treatment doctors can offer only eases minor symptoms for a short while. None can slow the actual brain damage that steals memory, thinking skills, and independence over time. There’s no pill that targets the root cause of the illness—and that’s exactly why a brand-new clinical trial is creating huge excitement among dementia patients, families, and brain researchers.
Run by biotech company NeuroTherapia, this trial tests a simple daily oral pill called NTRX-07. Unlike shots, infusions, or complicated medical treatments you might have heard of for Alzheimer’s, this drug is just two small tablets swallowed once a day. If it works as early lab tests suggest, it could be the first easy-to-use medicine that calms harmful brain inflammation and slows memory decline for people in the early to middle stages of Alzheimer’s or mild memory loss. This guide breaks down everything regular people need to know—no confusing medical jargon, no dense science formulas, just plain talk about who this trial is for, how it works, what participants go through, and why this drug could change the future of dementia care.
What Even Are Alzheimer’s and Mild Cognitive Impairment? Why We Desperately Need New Help
First, let’s clear up the biggest common misunderstanding: occasional forgetfulness from aging is nothing like Alzheimer’s.
Lots of seniors misplace keys or blank on a friend’s name now and then—that’s totally normal. MCI, mild cognitive impairment, is the halfway point between normal aging and full Alzheimer’s dementia. People with MCI notice consistent, worrying memory slips that disrupt daily life: forgetting recent conversations, failing to plan errands, struggling to keep track of bills, or mixing up familiar dates and locations. The catch? They can still live alone and handle most self-care without round-the-clock help. Without new treatment, roughly one in ten people with MCI will develop full Alzheimer’s every single year.
Once someone moves to mild or moderate Alzheimer’s, life shifts dramatically. Early-stage patients need help with complex tasks like travel or money management. Moderate patients struggle to recognize close family, grow confused day and night, and need daily support with bathing, eating, and taking medicine.
At the core of all this confusion and memory loss lies two silent, destructive problems inside the brain: toxic protein buildup and constant brain inflammation. Think of your brain like a well-oiled communication network between brain cells. Alzheimer’s creates sticky junk proteins that clog these connections, and triggers constant internal swelling that slowly kills off cells responsible for memory and logic. All drugs doctors use today only temporarily boost brain signals to mask confusion—they do nothing to clear that junk or calm the harmful inflammation eating away at brain tissue.
Some newer Alzheimer’s treatments are injectable medicines that clear one type of sticky protein, but they come with scary risks like brain swelling, require regular hospital visits for infusions, and still ignore the brain inflammation that speeds up decline. For millions of older adults who hate hospitals, fear needles, or can’t travel to clinics often, these injectable options aren’t practical long-term solutions. That massive gap in care is what NTRX-07 was created to fix.
NTRX-07 – The Easy Daily Pill That Targets Alzheimer’s Root Damage (No Scary Side Effects Like Cannabis)
NTRX-07 is a newly developed oral tablet, nicknamed MDA7 in early lab research. You might hear it described as a CB2 agonist—ignore that label, here’s what it means in simple terms:
Our brains have a natural defense system that controls swelling and cleans up harmful waste. One specific switch in this system lives on the brain’s cleanup cells, and NTRX-07 flips this protective switch safely. A common misconception: this drug is not marijuana, and it will never make users feel high, dizzy, or disoriented. The compound only targets brain cleanup cells, avoiding the brain receptors that create psychoactive, intoxicating effects linked to cannabis.
From animal testing before this human trial, researchers saw three game-changing benefits from NTRX-07:
- It calms constant, damaging brain inflammation that slowly destroys memory cells.
- It helps the brain’s built-in cleanup crew dissolve and flush away the toxic protein clumps that cause confusion.
- It protects the tiny “communication wires” between brain cells so memory and clear thinking stay intact longer.
Best of all for older patients and caregivers: the treatment is oral. Every morning, participants take two small tablets with water or food—no needles, no IV lines, no lengthy hospital infusions. The trial uses a fixed daily dose of 90mg of NTRX-07 split into two identical 45mg pills. Half the study group gets real NTRX-07, the other half gets identical-looking dummy pills (placebo) with zero active medicine, so researchers can tell exactly which changes come from the drug itself, not just the comfort of regular medical checkups.
The SPPN-AD Trial Basics – Who’s Running It, Where It Happens, Timeline & Participant Split
This is a Phase 2 clinical study, meaning it’s the second round of human testing for NTRX-07. Its main priority is checking if the pill is safe for older adults living with memory loss, while also gathering early clues about whether it improves brain health and cognition.
Core Trial Quick Facts
- Sponsor: NeuroTherapia, Inc., a US biotech firm focused on brain inflammation treatments
- Total Target Participants: 48 people total, split evenly into two groups of 24. One group takes real NTRX-07, the other takes matching placebo tablets.
- Full Trial Timeline:
- Started screening volunteers: March 2025
- Expected last participant finishes treatment: End of December 2025
- Entire study fully wrapped up with all data collected: June 2026
- Current Status: Actively recruiting eligible participants across Czechia and Poland
The study uses a gold-standard fair testing method called randomized quadruple blind placebo control. Translated simply: nobody involved knows who gets real medicine or dummy pills—participants, their family caregivers, doctors running tests, and specialists measuring brain changes all stay unaware of group assignments. This stops personal bias from skewing results, making the trial data far more reliable.
What Joining the Trial Actually Feels Like for a Volunteer (Step-by-Step, No Stressful Medical Lingo)
For anyone who qualifies, their full trial journey lasts 7 to 10 weeks total, split into three straightforward stages, with all medical testing and study medication provided free of charge. Every step is designed to be gentle and low-burden for seniors with memory impairment, with a trusted caregiver present at all clinic visits.
Stage 1: Screening (Up to 45 days before starting daily pills)
This phase only exists to make sure the volunteer fits all safety and illness criteria, and no hidden health risks would make participation unsafe. Required check-ins include:
- Full general health exam, heart screening, routine blood and urine work to check organ function
- Quick memory tests to confirm mild cognitive impairment or mild-moderate Alzheimer’s
- Brain scan (MRI) to rule out unrelated brain damage that could cause memory loss
- A simple spinal fluid test to confirm their memory issues stem from Alzheimer’s-related brain changes
- Caregiver verification: Every participant must live at home with a reliable family member or helper who sees them at least 10 hours weekly, to supervise daily pill-taking and drive them to appointments.
If all screening tests pass, volunteers are randomly placed into either the real drug group or placebo group and start the 28-day treatment phase. If any test flags a health risk, they cannot join the trial, and doctors share all screening results with them for their personal care.
Stage 2: 28 Days of Daily Tablet Dosing (Core Trial Period)
For four full weeks, volunteers swallow two matching tablets once each morning, watched over by their caregiver to ensure consistent daily use. During these 28 days, they make several short visits to the clinic for quick, painless assessments:
- Regular safety checks: Blood pressure, heart rate, brief physical exam to spot any side effects
- Repeat memory quizzes to track shifts in thinking and recall
- Blood and spinal fluid samples to measure how the drug travels through the body and reaches the brain
- Brain scan and simple brain wave tests to track swelling and brain activity changes
All new aches, fatigue, mood shifts, or other discomfort are noted down by staff at every visit to track safety.
Stage 3: Final Safety Follow-Up Visit (7 Days After Last Pill)
One week after finishing the 28-day pill schedule, volunteers come back for one last quick checkup. Staff review any delayed side effects that appeared after stopping the tablets, run basic blood work, and wrap up their participation entirely. No more testing or appointments are required after this single visit.
Who Can Join the Trial? Simple Eligibility Rules Everyone Can Understand
Who’s Allowed to Sign Up (Key Requirements)
- Age between 65 and 80 years old
- Officially diagnosed with mild cognitive impairment OR mild to moderate Alzheimer’s disease, confirmed via standard memory tests
- Have proof their memory loss comes from Alzheimer’s brain changes (via blood or spinal fluid biomarkers)
- Memory problems first appeared after age 60
- No serious ongoing depression
- Already taking stable standard Alzheimer’s medication for at least six months, with no plan to switch doses mid-trial
- Live at home with a consistent caregiver who can oversee daily pills and clinic trips
- Healthy weight range (55–110kg) with average body mass index
- Women must be past menopause or surgically unable to become pregnant; men must use reliable contraception during treatment and three months afterward
- Willing to complete all required scans, blood draws, and spinal fluid testing
Why This Small Trial Matters to Every Family Worried About Dementia
Right now, millions of older adults face a bleak outlook: their memory will keep fading, and doctors can only offer temporary symptom relief. The biggest flaw in existing treatment is that none address the brain inflammation that speeds up cell death. NTRX-07 fills this huge gap, with the massive bonus of being a simple oral pill instead of painful, inconvenient injections.
If this trial delivers promising safety and brain health signals, drug developers will launch multi-year large-scale trials to test long-term NTRX-07 use. In the best-case scenario, this daily tablet could one day become a standard early intervention for people with mild memory loss, slowing cognitive decline, letting patients live independently longer, and drastically cutting the emotional and financial burden on family caregivers.
Another meaningful detail: the study team plans to share all anonymous participant data publicly one year after the trial finishes in June 2026. Scientists worldwide will be able to study the results freely, speeding up global research into anti-inflammatory dementia treatments for all populations. Even if NTRX-07 itself needs further tweaks, the data from this trial will teach researchers critical lessons about how brain swelling impacts Alzheimer’s progression, paving the way for better dementia medicines down the line.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoRelated Clinical Trials
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer’s Disease
The goal of this clinical trial is to learn about how genetics and the response to stress predicts cognitive decline in individuals with mild cognitive impairment. The main question\[s\] it aims to answer are: * Does the hormone response to acute stress predict the degree of cognitive impairment following acute stress? * Do genes associated with the risk for Alzheimer’s disease influence the relationship between stress hormone response to stress and cognitive impairment following stress? * Do cognitive impairment following acute stress and genes associated with the risk for Alzheimer’s disease predict cognitive decline and change in biomarkers for Alzheimer’s disease 2 years later? Participants will have 3 in-person study visits. The first 2 will occur at baseline and the 3rd visit will occur 2 years later. During the visits, participants will provide blood and saliva samples, undergo a 10-minute social stress procedure, complete questionnaires, and take tests of memory and other thinking skills. Someone who knows the participant (a “study partner”) will be asked questions about the participant’s daily fuioning at the first and 3rd study visits.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoTranscranial Pulse Stimulation for Alzheimer’s Disease
TPS is a non-invasive therapeutic modality that uses focused, low-energy pulse stimulation to stimulate tissue regeneration and reduce inflammation. In the context of neurological disorders, it is hypothesized that TPS can modulate neuronal activity, enhance synaptic plasticity, and reduce neuroinflammation. It is a relatively new application in neurological disease treatment and is still under intense investigation.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoSemantic Recognition Task (SRT) in Alzheimer Disease
The goal of this study is to observe the outcomes of a semantic recognition task in Alzheimer Disease and discuss what this might add to clinical practice.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoMediators and Moderators of Auditory Training
The goal of this clinical trial is to learn how Auditory Training (AT) may help people better understand speech in noisy environments. As people get older, it becomes harder for them to hear speech clearly when there is background noise. This can be frustrating, and it can affect their independence and quality of life. AT is often used to support people with and without hearing loss, especially when a person is not a good candidate for a hearing aid or when amplification from a hearing aid does not improve performance. The investigators want to gather reliable data to understand how AT works and what affects its success. The main questions the trial aims to answer are: * How do different types of sounds influence the effectiveness of auditory training? * Which auditory training approaches are most successful in improving speech understanding? * How do personal traits impact the results of auditory training? The investigators will study a large and diverse group of 1,260 participants, including both young and older adults, to evaluate various auditory training approaches. You will: * Take part in auditory training sessions that include different types of auditory tasks. * Complete tests that measure how well they understand speech in both quiet and noisy settings. * Complete surveys on personal data like demographics, hearing challenges and other factors to help researchers understand what might influence training results. The investigators will measure and compare the results of these approaches to find out which ones are most effective. This could help people who are at risk of cognitive decline, like those at risk for Alzheimer’s disease.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoImproving PCP Advance Care Planning for People With ADRD
This study will test the Dementia Advance Care Planning (AD ACP) Toolkit intervention to usual care in facilitating goals of care (GOC) discussions between People Living with Dementia (PLwD) and primary care team members over an 18-month period. The primary outcome is to assess the frequency and quality of GOC discussions with PLwD. Secondary outcomes include the identification of preferred surrogates, assessment of decisional capacity, and the completion of portable ACP orders. This randomized clinical trial aims to determine if the AD ACP Toolkit can enhance ACP practices and improve care planning outcomes for PLwD compared to the standard care approach.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoAssociation of Transcranial Alternating Current Stimulation with Digital Cognitive Training for Cognitive Remediation in Older Adults
BACKGROUND Cognitive decline in older adults, especially those who develop Mild Cognitive Impairment and Alzheimer’s Disease, currently has limited options of pharmacological treatments, with modest efficacy. Digital Cognitive Training (DCT) and Transcranial Alternating Current Stimulation (tACS) are two promising tools for cognitive remediation in this population. In this exploratory study, we investigate feasibility, tolerability and preliminary effects of the association of both interventions in older adults with cognitive complaints. METHODS Older adults with cognitive complaints are being enrolled for this study, which comprises 5 daily sessions of 30 minutes of DCT using the BrainHQ platform while simultaneously receiving theta tACS (6Hz, 1.6mA) targeting the Left Dorsolateral Prefrontal Cortex.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoSafety and Target Engagement of Centella Asiatica in Cognitive Impairment
This clinical trial is focused on determining whether biological signatures of target engagement by a Centella asiatica water extract product administered orally for 6 weeks can be measured in comparison to placebo. This study will also assess the safety and tolerability of the Centella asiatica water extract product.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoPsychological Counseling Program for Alzheimer’s Patients’ Caregivers
Purpose: To investigate the effects of a psychological counseling program (PsychoCP) applied to caregivers of Alzheimer’s patients on perceived stress, psychological well-being and care burden. Design: The study will be conducted in a pre-test post-test control group, randomized controlled experimental research design. Method: The study is planned to be carried out in Bağcılar Municipality Vefahâne Life Center, Antalya Alzheimer Patients and Patient Relatives Meeting Center and Osmaniye Family and Social Policies Directorate. The sample of the study will consist of 80 caregivers. They will be assigned to intervention (n=40) and control groups (n=40) by randomization. Hypotheses Hypothesis1: The perceived stress level of caregivers who received PsychoDP is lower than those who did not receive PsychoCP. Hypothesis2: The psychological well-being levels of caregivers who received PsychoDP are higher than those who did not receive PsychoCP. Hypothesis3: The care burden of caregivers who received PsychoDP is lower than those who did not receive PsychoCP.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoUsing the EHR to Advance Genomic Medicine Across a Diverse Health System
Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation and sustainable. The investigators propose an entirely new approach for the implementation of genomic medicine, supported by the leadership of Penn Medicine, investigating the use of non-geneticist clinician and patient nudges in the delivery of genomic medicine through a pragmatic randomized clinical trial, addressing NHGRI priorities. Our application is highly conceptually and technically innovative, building upon expertise and infrastructure already in place. Innovative qualities of our proposal include: 1) Cutting edge EHR infrastructure already built to support genomic medicine (e.g., partnering with multiple commercial genetic testing laboratories for direct test ordering and results reporting in the EHR); 2) Automated EHR-based direct ordering or referring by specialist clinicians (i.e., use of replicable modules that enable specialist clinicians to order genetic testing through Epic Smartsets, including all needed components, such as populated gene lists, smartphrases, genetic testing, informational websites and acknowledgement e-forms for patient signature); 3) EHR algorithms for accurate patient identification (i.e., electronic phenotype algorithms to identify eligible patients, none of which currently have phenotype algorithms present in PheKB; 4) Behavioral economics-informed implementation science methods: This trial will be the first to evaluate implementation strategies informed by behavioral economics, directed at clinicians and/or patients, for increasing the use of genetic testing; further it will be the first study in this area to test two forms of defaults as a potential local adaptation to facilitate implementation (ordering vs. referring); and 5) Dissemination: In addition to standard dissemination modalities,PheKB95, GitHub and Epic Community Library, the investigators propose to disseminate via AnVIL (NHGRI’s Genomic Data Science Analysis, Visualization, and Informatics Lab-Space). Our results will represent an entirely new paradigm for the provision of genomic medicine for patients in whom the results of genetic testing change medical management.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoAn Open-Label Study of ML-007C-MA in Adults With Alzheimer’s Disease Psychosis
ML-007C-MA-222 is a 52-week, flexible-dose, open-label extension study designed to evaluate the long-term safety, tolerability, and effectiveness of ML007C-MA in participants with ADP who have completed the antecedent study (ie, Study ML-007C-MA-221).
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoDORA and LP in Alzheimer’s Disease Biomarkers
The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer’s disease.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoPromoting Physical Activity in Older Hispanic/Latino(a) Adults
In this randomized controlled trial, study staff will randomize 130 Hispanic/Latino adults without dementia and over age 55 from Southern California and from Kaiser Permanente Washington (State) to either the culturally adapted De Pie physical activity intervention or an active comparison program focusing on general brain health topics. The purpose of this study is to determine if 12 weeks of the culturally adapted and fully remote De Pie y a Movernos intervention improves self-efficacy, habit strength, social support, and enjoyment for physical activity (PA), thus promoting adherence to moderate-intensity physical activity (MIPA) guidelines (150 minutes/week).
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoEvaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders
The goal of this clinical trial is to compare the Hospital Elder Life Program (HELP) with a family-augmented version of HELP (FAM-HELP), that includes family members and care partners, for the prevention of delirium in older patients during hospital admission. The main objectives of the trial are the following: 1. To compare the effectiveness of FAM-HELP and HELP in reducing both the incidence of delirium and its severity. 2. To compare the effectiveness of FAM-HELP and HELP in improving patient- and family-reported outcomes. 3. To explore the implementation context, process, and outcomes of the FAM-HELP program in diverse hospital settings.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoPhase 2 – Rhythmic Light Therapy for Alzheimer’s Disease Patients
Participants will randomly be placed into one of four groups and experience one of the four following conditions: (1) a placebo light that provides a 40 hertz (Hz) flicker (rhythmic light \[RL\]); (2) a placebo light with a random flicker (placebo condition for rhythmic light); (3) a light source that will stimulate the circadian system and provides a 40 Hz flicker (RL); or (4) a light source that will stimulate the circadian system and provides a random flicker (placebo condition for rhythmic light). Following a baseline week, participants will experience his/her assigned lighting condition for two hours in the morning for 8 weeks. After a 4-week washout period, a final round of assessments will be obtained. Study assessments (except for the Pittsburgh Sleep Quality Index and Montreal Cognitive Assessment) will be collected at the end of each week, for a total of 8 assessments.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoACP-204 in Adults With Alzheimer’s Disease Psychosis
This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP * Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first. * Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B will be performed independently of each other and will commence after enrollment of Part 1. All 3 substudies will be analyzed independently of each other. Each substudy individually will consist of a screening period (up to 49 days); a double-blind treatment period (6 weeks); a safety follow-up period (30 days) for patients not rolling over into an open-label extension study; and vital status follow-up (for patients who terminated their substudy early).
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoCognitive-motor Training in Community-dwelling Older People With Mild Cognitive Impairment
As the global population ages, the prevalence of mild cognitive impairment (MCI) among older adults, which ranges from 5% to 40%, is expected to rise. MCI significantly increases the risk of developing Alzheimer’s disease and is associated with a heightened risk of falls, with evidence suggesting that individuals with MCI have a fall risk five times greater than their cognitively intact peers. While cognitive and physical impairments in MCI are recognized, targeted interventions addressing both aspects are needed. This study aims to evaluate the effectiveness of the Smart±step exergaming program, an interactive system combining cognitive and motor training through computer-based stepping tasks, in reducing risk of falls, fall rate and improving physical, cognitive, psychological, neurophysiological, and quality of life outcomes in community-dwelling older adults with MCI. Previous research indicates that combined cognitive-motor interventions can improve balance and cognitive outcomes, but evidence on their efficacy in reducing falls is limited. The study will assess whether the Smart±step program, previously shown to be effective in cognitively healthy populations, can also significantly reduce risk of fall, fall rates and enhance overall fuion in older people with MCI. If successful, the program could offer substantial benefits by lowering fall-related costs and disabilities, with potential for global adaptation and implementation.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoVestibular Therapy in Alzheimer’s Disease
Nearly 2 out of 3 patients with Alzheimer’s disease (AD) experience problems with balance and mobility, which places such patients at increased risk of falling. The vestibular (inner ear balance) system plays an important role in balance stability, and vestibular therapy (VT) is well-known to improve balance fuion in healthy older adults. In this study, the investigators will conduct a first-in-kind randomized clinical trial to evaluate whether vestibular therapy improves reduces falls in patients with AD, in whom this treatment has never been studied.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer’s disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoA Study of CM383 in Patients With Alzheimer’s Disease Related Mild Cognitive Impairment and Mild Alzheimer’s Disease
This is a randomized, double-blind, placebo-controlled and multiple dose escalation phase Ib study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM383 in patients with Alzheimer’s disease related mild cognitive impairment and mild Alzheimer’s disease.
PDF$29 only! Buy Clinical Trial Full Report With Contact InfoDaridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease
DARIDOR-ALZ is a phase IV clinical trial designed to evaluate both the efficacy and safety of daridorexant, a selective dual orexin receptor antagonist that blocks the actions of the orexin neuropeptides at both orexin-1 and orexin-2 receptors, in selected populations of MCI and mild-to-moderate AD patients with insomnia complaints.
PDF$29 only! Buy Clinical Trial Full Report With Contact Info